The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 510-518

  Koren Gluzer, Marie ^a   Aviram, Michael ^a   Meilin, Edna ^a   Hayek, Tony ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cells; Diabetes; Oxidative stress; Paraoxonase 1

Indexed keywords

ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ARYLDIALKYLPHOSPHATASE 1; GLUCOSE; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN; INSULIN; MUTANT PROTEIN; POLYPHENOL; PUNICALAGIN; RECOMBINANT ENZYME; RECOMBINANT PARAOXONASE 1; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL GROUP; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CATALYSIS; CELL LEVEL; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PERITONEUM MACROPHAGE; POMEGRANATE JUICE; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; CELL LINE; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN-SECRETING CELLS; LIPOPROTEINS, HDL; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; OXIDATIVE STRESS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 82955195724     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.119     Document Type: Article

References (50)

1. Getz G.S., Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004, 15:261-267.
2. Hunt J.V., Smith C.C., Wolff S.P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990, 39:1420-1424.
3. Myint T., Hoshi S., Ookawara T., Miyazawa N., Suzuki K., Taniguchi N. Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. Biochim Biophys Acta 1995, 1272:73-79.
4. Kaneto H., Fujii J., Myint T., Miyazawa N., Islam K.N., Kawasaki Y., et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Biochem J 1996, 32(Pt 3):855-863.
5. Kaneto H., Kajimoto Y., Miyagawa J., Matsuoka T., Fujitani Y., Umayahara Y., et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 1999, 48:2398-2406.
6. Xu B., Moritz J.T., Epstein P.N. Overexpression of catalase provides partial protection to transgenic mouse beta cells. Free Radical Biol Med 1999, 27:830-837.
7. Chen H., Carlson E.C., Pellet L., Moritz J.T., Epstein P.N. Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 2001, 50:2040-2046.
8. Meier J.J. Beta cell mass in diabetes: a realistic therapeutic target?. Diabetologia 2008, 51:703-713.
9. Weir G.C., Laybutt D.R., Kaneto H., Bonner-Weir S., Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001, 50(Suppl. 1):S154-S159.
10. Aviram M., Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005, 16:393-399.
11. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998, 18:1617-1624.
12. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101:2510-2517.
13. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998, 101:1581-1590.
14. Rozenberg O., Shih D.M., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.
15. Mastorikou M., Mackness M., Mackness B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes 2006, 55:3099-3103.
16. Sampson M.J., Braschi S., Willis G., Astley S.B. Paraoxonase-1, (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes. Clin Sci (Lond) 2005, 109:189-197.
17. Rozenberg O., Shiner M., Aviram M., Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radical Biol Med 2008, 44:1951-1959.
18. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
19. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 1978, 52:302-310.
20. el-Saadani M., Esterbauer H., el-Sayed M., Goher M., Nassar A.Y., Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989, 30:627-630.
21. Hu M.L., Dillard C.J., Tappel A.L. In vivo effects of aurothioglucose and sodium thioglucose on rat tissue sulfhydryl levels and plasma sulfhydryl reactivity. Agents Actions 1988, 25:132-138.
22. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci U S A 2004, 101:482-487.
23. Khersonsky O., Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 2006, 281:7649-7656.
24. Gaidukov L., Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005, 44:11843-11854.
25. D'Ambra R., Surana M., Efrat S., Starr R.G., Fleischer N. Regulation of insulin secretion from beta-cell lines derived from transgenic mice insulinomas resembles that of normal beta-cells. Endocrinology 1990, 126:2815-2822.
26. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992, 5:227-231.
27. Johnston R.B., Keele B.B., Misra H.P., Lehmeyer J.E., Webb L.S., Baehner R.L., et al. The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes. J Clin Invest 1975, 55:1357-1372.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
30. Metz S.A., Rabaglia M.E., Stock J.B., Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J 1993, 295(Pt 1):31-40.
31. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 1983, 30:111-118.
32. Fryirs M.A., Barter P.J., Appavoo M., Tuch B.E., Tabet F., Heather A.K., et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010, 30:1642-1648.
33. Hayek T., Hussein K., Aviram M., Coleman R., Keidar S., Pavoltzky E., et al. Macrophage foam-cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis 2005, 183:25-33.
34. Deakin S., Leviev I., Nicaud V., Brulhart Meynet M.C., Tiret L., James R.W. Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. J Clin Endocrinol Metab 2002, 87:1268-1273.
35. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol Med 1999, 26:892-904.
36. Patel B.N., Mackness M.I., Harty D.W., Arrol S., Boot-Hanford R.P., Durrington P.N. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta (BBA) - Gen Subj 1990, 1035:113-116.
37. Kim W.-H., Lee J.W., Suh Y.H., Hong S.H., Choi J.S., Lim J.H., et al. Exposure to chronic high glucose induces β-cell apoptosis through decreased interaction of glucokinase with mitochondria. Diabetes 2005, 54:2602-2611.
38. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
39. Moriscot C., Pattou F., Kerr-Conte J., Richard M.J., Lemarchand P., Benhamou P.Y. Contribution of adenoviral-mediated superoxide dismutase gene transfer to the reduction in nitric oxide-induced cytotoxicity on human islets and INS-1 insulin-secreting cells. Diabetologia 2000, 43:625-631.
40. Tanaka Y., Gleason C.E., Tran P.O., Harmon J.S., Robertson R.P. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A 1999, 96:10857-10862.
41. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., Aviram M., Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radical Biol Med 2003, 34:774-784.
42. Watkins D., Cooperstein S.J., Lazarow A. Effect of sulfhydryl reagents on permeability of toadfish islet tissue. Am J Physiol 1970, 219:503-509.
43. Watkins D.T., Moore M. Effect of sulfhydryl-binding reagents on insulin release from isolated secretion granules. Endocrinology 1974, 95:485-491.
44. May J.M. The inhibition of hexose transport by permeant and impermeant sulfhydryl agents in rat adipocytes. J Biol Chem 1985, 260:462-467.
45. Tseng C.H. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol 2004, 197:67-83.
46. Bourquard N., Ng C.J., Reddy S.T. Impaired hepatic insulin signalling in PON2-deficient mice: a novel role for the PON2/apoE axis on the macrophage inflammatory response. Biochem J 2011, 436:91-100.
47. Rosenblat M., Karry R., Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006, 187:74-81.
48. Fuhrman B., Volkova N., Aviram M. Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients. Nutrition 2010, 26:359-366.
49. Deakin S.P., Bioletto S., Bochaton-Piallat M.L., James R.W. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radical Biol Med 2011, 50:102-109.
50. Kaestner K.H., Lee C.S., Scearce L.M., Brestelli J.E., Arsenlis A., Le P.P., et al. Transcriptional program of the endocrine pancreas in mice and humans. Diabetes 2003, 52:1604-1610.